Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: An ongoing dilemma or an unnecessary dispute?

Medical Mycology, Supplement

Volumn 36, Issue 1, 1998, Pages 95-105

  Casadevall, A ^a   Cassone, A ^b   Bistoni, F ^c   Cutler, J E ^d   Magliani, W ^e   Murphy, J W ^f   Polonelli, L ^e   Romani, L ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d MONTANA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF PARMA   (Italy)

^f UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Antibody; Candida albicans; Cell mediated immunity; Cryptococcus neoformans; Humoral immunity; T cell; Vaccine

Indexed keywords

ANTIBODY; POLYCLONAL ANTIBODY;

CANDIDA ALBICANS; CELLULAR IMMUNITY; CONFERENCE PAPER; CRYPTOCOCCUS NEOFORMANS; HUMORAL IMMUNITY; MYCOSIS; T LYMPHOCYTE; VACCINATION;

ANIMALS; ANTIBODIES, FUNGAL; CANDIDA ALBICANS; CANDIDIASIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; HUMANS; IMMUNITY, CELLULAR; MICE;

EID: 0032311182     PISSN: 09668454     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (82)

1. Polonelli L, De Bernardis F, Conti S, et al. Human natural yeast killer toxin-like candidacidal antibodies. J Immun 1996; 156: 1880-5.
2. Magliani W, Conti S, De Bernardis F, et al. Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nat Biotech 1997; 15: 155-8.
3. Mourad S, Friedman L. Pathogenicity of Candida. J Bacteriol 1961; 81: 550-6.
4. Mourad S, Friedman L. Passive immunization of mice against Candida albicans. Sabouraudia 1968; 6: 103-5.
5. Pearsall NN, Adams BL, Bunni R. Immunologic responses to Candida albicans. III. Effects of passive transfer of lymphoid cells or serum on murine candidiasis. J Immun 1978; 120: 1176-80.
6. Casadevall A. Antibody and invasive fungal infections. Infect Immun 1995; 63: 4211-8.
7. Matthews RC, Burnie JP, Howat D, Rowland T, Walton F. Autoantibody to heat-shock protein 90 can mediate protection against systemic candidosis Immunology 1991; 74: 20-4.
8. Matthews R, Burnie J. Antibodies against Candida: potential therapeutics? Trends Microbiol 1996; 4: 354-8.
9. Matthews R, Hodgetts S, Burnie J. Preliminary assessment of a human recombinant antibody fragment to hsp90 in murine invasive candidiasis. J Infect Dis 1995; 171: 1668-71.
10. Cuff CF, Packer BJ, Rogers TJ A further characterization of Candida ablicans-induced suppressor B-cell activity. Immunology 1989; 68: 80-6.
11. Tavares D, Ferreira P, Vilanova M, Videira A, Arala Chaves M. Immunoprotection against systemic candidiasis in mice. Infect Immun 1995; 7: 785-96.
12. Polonelli L, Morace G. Yeast killer toxin-like anti-idiotypic antibodies. J Clin Microbiol 1988; 26: 602-4.
13. Casanova M, Martmez JP, Chaffin WL. Fab fragments from a monoclonal antibody against a germ tube mannoprotem block the yeast-to-mycelium transition in Candida albicans. Infect Immun 1990; 58: 3810-2.
14. Cassone A, Boccanera M, Adriani D, Santoni G, De Bernardis F. Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection. Infect Immun 1995; 63: 2619-24.
15. Cassone A, Conti S, De Bernardis F, Polonelli L. Antibodies, killer toxins and antifungal immunoprotection: a lesson from nature? Immun Today 1997; 18: 164-9.
16. Han Y, Van Rooijen N, Cutler JE. Binding of Candida albicans yeast cells to mouse popliteal lymph node tissue is mediated by macrophages. Infect Immun 1993; 61: 3244-9.
17. Kanbe T, Han Y, Redgrave B, Riesselman MH, Cutler JE. Evidence that mannans of Candida albicans are responsible for adherence of yeast forms to spleen and lymph node tissue. Infect Immun 1993; 61: 2578-84.
18. Shibata N, Ikuta K, Imai T, et al. Existence of branched side chains in the cell wall mannan of the pathogenic yeast, Candida albicans. J Biol Chem 1995; 270: 1113-22.
19. Li RK, Cutler JE Chemical definition of an epitope/adhesin molecule on Candida albicans. J Biol Chem 1993; 268: 18293-9.
20. Kanbe T, Cutler JE. Evidence for adhesin activity in the acid-stable moiety of the phosphomannoprotein complex of Candida albicans. Infect Immun 1994; 62: 1662-8.
21. Han Y, Cutler JE. Antibody response that protects against disseminated candidiasis Infect Immun 1995; 63: 2714-9.
22. Han Y, Cutler JE. Assessment of a mouse model of neutropenia and the effect of an anti-candidiasis monoclonal antibody in these animals. J Infect Dis 1997; 175: 1169-75.
23. Bodey GP. Fungal infections complicating acute leukemia. J Chron Dis 1996; 19: 667-87.
24. Odds FC. and Candida Candidiosis, 2nd edn. London: Baillière-Tindall, 1988.
25. Coogan MM, Sweet SP, Challacombe SJ. Immunoglobulin A (IgA), IgA1, and IgA2 antibodies to Candida albicans in whole and parotid saliva in human immunodeficiency virus infection and AIDs. Infect Immun 1994; 62: 892-6.
26. Matthews R, Burnie J, Smith D, et al. Candida and AIDS: evidence for protective antibody. Lancet 1988; ii: 263-5.
27. Polonelli L, De Bernardis F, Boccancra M, et al. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J Immun 1994; 152: 3175-81.
28. Challacombe SJ. Immunologic aspects of oral candidiasis. Oral Surg, Oral Med, Oral Pathol 1994; 78: 202-10.
29. H2-like switch in candidiasis: new perspectives for therapy. Trends Microbiol 1995; 3: 237-40.
30. + T helper cell development in interleukin-6-deficient mice infected with Candida albicans. J Exper Med 1996; 183: 1345-55.
31. Romani L, Puccetti P, Bistoni F. Biological role of helper T-cell subsets in candidiasis. Chem Immun 1995; 63: 113-37.
32. Nussbaum G, Yuan R, Casadevall A, Scharff MD. Immunoglobulin G3 blocking antibodies to Cryptococcus neoformans. J Exper Med 1996; 183: 1905-9.
33. Pirofski L, Casadevall A. Antibody immunity to Cryptococcus neoformans: Paradigm for antibody immunity to the fungi? Zent Bakter 1996; 284: 475-95.
34. Polonelli L, Morace G. Reevaluation of the yeast killer phenomenon. J Clin Microbiol 1986; 24: 866-9.
35. Polonelli L, Morace G. Production and characterization of yeast killer toxin monoclonal antibodies. J Clin Microbiol 1987; 25: 460-2.
36. Polonelli L, Fanti F, Conti S, et al. Detection by immunofluorescent anti-idiotypic antibodies of yeast killer toxin cell wall receptors of Candida albicans. J Immun Meth 1990; 132: 205-9.
37. Polonelli L, Lorenzini R, De Bernardis F, et al. Idiotypic vaccination: immunoprotection mediated by anti-idiotypic antibodies with antibiotic activity. Scan J Immun 1993; 37: 105-10.
38. Polonelli L, Séguy N, Conti S, et al. Monoclonal yeast killer toxin-like candidacidal antiidiotypic antibodies. Clin Diag Lab Immun 1997; 4: 142-6.
39. Aliouat EM, Cailliez JC, Séguy N, et al. Inhibitory effect of a yeast killer toxin to the in vitro Pneumocystis carinii attachment. Serodiag Immunother infect Dis 1993; 5: 102-6.
40. Séguy N, Polonelli L. Conti S, et al. In vitro decrease of ratderived Pneumocystis carinii attachment induced by human natural yeast killer toxin-like antiidiotypic candidacidal antibodies. J Euk Microbiol 1996; 43: 27S.
41. Kwon-Chung KJ, Bennett JE. Medical Mycology. Philadelphia: Lea & Febiger. 1992.
42. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995; 8: 515-48.
43. Powderly WG. Therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1992; 14: S54-9.
44. Spitzer ED, Spitzer SG, Freundlich LF, Casadevall A. Persistence of the initial infection in recurrent cryptococcal meningitis. Lancet 1993; 341: 505-96.
45. Murphy JW. Mechanisms of natural resistance to human pathogenic fungi. Ann Rev Microbiol 1991; 45: 509-38.
46. Murphy JW. Cell-mediated immunity. In: Howard DH. Miller JD, eds. The Mycota VI Human and Animal Relationships, Vol VI. Berlin: Springer-Verlag, 1996: 67-97.
47. Cauley LK, Murphy JW. Response of congenitally athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection. Infect Immun 1979; 23: 644-51.
48. Huffnagle GB, Yates JL, Lipscomb MF. T cell-mediated immunity in the lung: a Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice. Infect Immun 1991; 59: 1423-33.
49. Janeway CA, Travers P Immunobiology. The Immune System in Health and Disease, 2nd edn New York: Garland Publishing Inc. 1996.
50. Fung PY, Murphy JW. In vitro interactions of immune lymphocytes and Cryptococcus neoformans. Infect Immun 1982; 36: 1128-38.
51. Muth SM, Murphy JW. Direct anticryptococcal activity of lymphocytes from Cryptococcus neoformans-immunized mice. Infect Immun 1995; 63: 1637-44.
52. Muth SM, Murphy JW. Effects of immunization with Cryptococcus neoformans cells or cryptococcal culture filtrate antigen on the direct anticryptococcal activities of murine T lymphocytes. Infect Immun 1995; 63: 1645-51.
53. + T cells in vivo decreases pulmonary clearance of a moderately virulent strain of Cryptococcus neoformans. J Lab Clin Med 1993; 121: 765-73.
54. Mody CH, Paine R, Jackson C, Chen GH, Toews GB. CD8 cells play a critical role in delayed type hypersensitivity to intact Cryptococcus neoformans. J Immun 1994; 152: 3970-9.
55. Fidel PL, Murphy JW Effects of cyclosporin A on the cells responsible for the anticryptococcal cell-mediated immune response and its regulation Infect Immun 1989; 57: 1158-64.
56. Fidel PL, Murphy JW. Characterization of a cell population which amplifies the anticryptococcal delayed-type hypersensitivity response. Infect Immun 1990; 58: 393-8.
57. Buchanan KL, Murphy JW. Regulation of cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect Immun 1994; 62: 2930-9.
58. Murphy JW. Cytokine profiles associated with induction of the anticryptococcal cell-mediated immune response. Infect Immun 1993; 61: 4750-9.
59. Aguirre KM, Johnson LL. A role for B cells in resistance to Cryptococcus neoformans in mice. Infect Immun 1997; 65: 525-30.
60. + T cell-dependent acquired state of immunity that protects the brain against Cryptococcus neoformans. J Immun 1994; 152: 2344-50.
61. + T cells. J Exper Med 1991; 173: 793-800.
62. +) lymphocytes in vivo impairs murine host defense to Cryptococcus neoformans. J Immun 1990; 144: 1472-7.
63. Murphy JW. Clearance of Cryptococcus neoformans from immunologically suppressed mice. Infect Immun 1989; 57: 1946-52.
64. Dromer F, Charreire J, Contrepois A, Carbon C, Yeni P. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun 1987; 55: 749-52.
65. Dromer F, Salamero J, Contrepois A, Carbon C, Yeni P. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect Immun 1987; 55: 742-8.
66. Mukherjee J, Scharff MD, Casadevall A. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun 1992; 60: 4534-41.
67. Mukherjee S, Lee S, Mukherjee J, Scharff MD, Casadevall A. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun 1994; 62: 1079-88.
68. Sanford JE, Lupan DM, Schlagetter AM, Kozel TR. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect Immun 1990; 58: 1919-23.
69. Gigliotti F, Hughes WT. Passive immunoprophy laxis with specific monoclonal antibodies confers partial protection against Pneumocystis carinii pneumonitis in animal models. J Clin Invest 1988; 81: 1666-8.
70. Mukherjee J, Pirofski L, Scharff MD, Casadevall A. Antibody mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc Natl Acad Sci USA 1993; 90: 3636-40.
71. Yuan R, Casadevall A, Spira G, Scharff MD. Isotype switching from IgG3 to IgG1 converts a non-protective murine antibody to C. neoformans into a protective antibody. J Immun 1995; 154: 1810-6.
72. Mukherjee S, Lee SC, Casadevall A. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun 1995; 63: 573-9.
73. Mukherjee J, Nussbaum G, Scharff MD, Casadevall A. Protective and non-protective monoclonal antibodies to Cryptococcus neoformans originating from one B-cell. J Exper Med 1995; 181: 405-9.
74. Nussbaum G, Cleare W, Casadevall A, Scharff MD, Valadon P. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exper Med 1997; 185: 685-94.
75. Dromer F, Perronc C, Barge J, Vilde JL, Yeni P. Role of IgG and complement component C5 in the initial course of experimental cryptococcosis. Clin Exper Immun 1989; 78: 412-7.
76. Mukherjee S, Feldmesser M, Casadevall A J774 Murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins. J Infect Dis 1996; 173: 1222-31.
77. Schlagetter AM, Kozel TR. Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide. Infect Immun 1990; 58: 1914-8.
78. Goldman DL, Lee SC, Casadevall A. Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect Immun 1995; 63: 3448-53.
79. Mozaffanan N, Berman JW, Casadevall A. Immune complexes increase nitric oxide production by interferon-gamma-stimulated murine macrophage-like J774.16 cells. J Leak Biol 1995; 57: 657-62.
80. Feldmesser M, Casadevall A. Effect of serum IgG1 against murine pulmonary infection with Cryptococcus neoformans. J Immun 1997; 158: 790-9.
81. Yuan R, Casadevall A, Oh J, Scharff MD. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc Natl Acad Sci USA 1997; 94: 2483-8.
82. Mukherjee J, Scharff MD, Casadevall A. Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains. Infect Immun 1995; 63: 3353-9.